A meta-analysis showed that mTOR inhibitor-based regimens significantly reduce early recurrence rates after liver transplantation for HCC and improve recurrence-free survival and overall survival compared to CNI-based regimens [89]. Here, MTOR is linked to hepatocellular carcinoma.